Diagnostic complexe de la thyroïde
Toutes directions
Diagnostic complexe de la thyroïde
Toutes directions

Les Meilleurs doctors pour votre Diagnostic complexe de la thyroïde - TOP 70 des médecins

Le contenu respecte la Politique Éditoriale Bookimed et est examinée médicalement par
Fahad Mawlood - Praticien généraliste. Lauréat de 4 prix scientifiques. Diplômé en Asie occidentale. Ancien Chef d'une équipe médicale aidant les patients arabes. Aujourd'hui responsable du traitement des données et de l'exactitude du contenu médical.
Nuri Alper Sahbaz
General surgeon
19 années d'expérience
4.5
138 avis
Turquie, Istanbul
Hisar Intercontinental Hospital

Nuri Alper Sahbaz

General surgeon
19 années d'expérience

Assoc. Prof. Nuri Alper Şahbaz is an experienced doctor with medical education from Istanbul University, Cerrahpaşa Faculty of Medicine, and scientific and clinical experience from Baylor College of Medicine and The University of Texas Medical School. He is specialized in endocrine surgery (thyroid, parathyroid, adrenal gland and neuroendocrine tumors) and has performed over 2000 successful surgeries in this area. He also specializes in laparoscopic and minimally invasive surgeries, as well as in diagnostic and therapeutic gastrointestinal system endoscopy.

Lire la suite

Assoc. Prof. Nuri Alper Şahbaz is an experienced doctor with medical education from Istanbul University, Cerrahpaşa Faculty of Medicine, and scientific and clinical experience from Baylor College of Medicine and The University of Texas Medical School. He is specialized in endocrine surgery (thyroid, parathyroid, adrenal gland and neuroendocrine tumors) and has performed over 2000 successful surgeries in this area. He also specializes in laparoscopic and minimally invasive surgeries, as well as in diagnostic and therapeutic gastrointestinal system endoscopy.

Lire la suite
4.5
138 avis
Visite du médecin prix sur demande
Thérapie à l'iode radioactif $4000 - $5000
Thyroïdectomie $5000 - $7500
Plus de traitements
Suleyman Hilmi Ipekci
Endocrinologist
25 années d'expérience
4.5
138 avis
Turquie, Istanbul
Hisar Intercontinental Hospital

Suleyman Hilmi Ipekci

Endocrinologist
25 années d'expérience
Assoc. Prof. Süleyman İPEKÇİ, M.D. is a physician specializing in diabetes, thyroid and diabetes diseases, thyroid cancers, pituitary diseases, adrenal gland diseases, and hormone disorders. He graduated from Cerrahpaşa School of Medicine, Istanbul University in 1999, completed his residency in 2005, his fellowship in 2010, and his training for Associate Professorship in 2016. He has authored 42 scientific articles published in international scientific journals and has participated in numerous national and international conferences and projects.Lire la suite
Assoc. Prof. Süleyman İPEKÇİ, M.D. is a physician specializing in diabetes, thyroid and diabetes diseases, thyroid cancers, pituitary diseases, adrenal gland diseases, and hormone disorders. He graduated from Cerrahpaşa School of Medicine, Istanbul University in 1999, completed his residency in 2005, his fellowship in 2010, and his training for Associate Professorship in 2016. He has authored 42 scientific articles published in international scientific journals and has participated in numerous national and international conferences and projects.
Lire la suite
4.5
138 avis
Visite du médecin prix sur demande
Thérapie à l'iode radioactif $4000 - $5000
Thyroïdectomie $5000 - $7500
Plus de traitements
Suleyman Hilmi Aksoy
Radiologist
22 années d'expérience
4.5
138 avis
Turquie, Istanbul
Hisar Intercontinental Hospital

Suleyman Hilmi Aksoy

Radiologist
22 années d'expérience
Le Dr Hilmi Aksoy est né en 1974 et a obtenu son diplôme à l'école de médecine de Çapa de l'université d'Istanbul en 1998. Il a effectué son internat en radiodiagnostic et radiologie interventionnelle à l'école de médecine de Cerrahpaşa en 2002. Il a participé à 13 congrès locaux et internationaux avec des présentations orales et écrites. Ses domaines d'intérêt médical comprennent la radiologie diagnostique, la téléradiologie et la radiologie interventionnelle. Il a travaillé à l'hôpital intercontinental de Hisar, à l'hôpital aérien de Merzifon, au centre Emar d'Istanbul et à l'hôpital de formation et de recherche de Haseki.Lire la suite
Le Dr Hilmi Aksoy est né en 1974 et a obtenu son diplôme à l'école de médecine de Çapa de l'université d'Istanbul en 1998. Il a effectué son internat en radiodiagnostic et radiologie interventionnelle à l'école de médecine de Cerrahpaşa en 2002. Il a participé à 13 congrès locaux et internationaux avec des présentations orales et écrites. Ses domaines d'intérêt médical comprennent la radiologie diagnostique, la téléradiologie et la radiologie interventionnelle. Il a travaillé à l'hôpital intercontinental de Hisar, à l'hôpital aérien de Merzifon, au centre Emar d'Istanbul et à l'hôpital de formation et de recherche de Haseki.
Lire la suite
4.5
138 avis
Visite du médecin prix sur demande
Thérapie à l'iode radioactif $4000 - $5000
Thyroïdectomie $5000 - $7500
Plus de traitements
Zuhal Tanzer
Endocrinologist
35 années d'expérience
4.4
42 avis
Turquie, Istanbul
Lokman Hekim Istanbul Hospital

Zuhal Tanzer

Endocrinologist
35 années d'expérience
Le docteur Zuhal Tanzer est spécialiste des maladies internes.Lire la suite
Le docteur Zuhal Tanzer est spécialiste des maladies internes.
Gokhan Yilmaz
Colorectal surgeon
13 années d'expérience
Turquie, Istanbul
Medipol University Pendik Hospital

Gokhan Yilmaz

Colorectal surgeon
13 années d'expérience

Né en 1981 à Erzincan. Après avoir terminé le lycée Beşiktaş Atatürk Anadolu en 1999, il est entré à l'université d'Istanbul Çapa, à la faculté de médecine. 

 

En 2005, j'ai obtenu mon master et j'ai commencé à pratiquer à l'hôpital d'État de Yüksekova. Il a obtenu son doctorat à l'hôpital de formation et de recherche Okmeydanı dans le service de chirurgie générale. En tant que spécialiste en chirurgie générale, il a travaillé à l'hôpital d'État Zonguldak Atatürk pendant 5 ans et à l'hôpital de formation et de recherche Sancaktepe Şehit Prof. Dr. İlhan Varank pendant 3 ans. 

 

A travaillé en tant que professeur adjoint à l'université Medipol d'Istanbul, au département de chirurgie générale. Travaille actuellement à l'hôpital Pendik de l'université Medipol.

Lire la suite

Né en 1981 à Erzincan. Après avoir terminé le lycée Beşiktaş Atatürk Anadolu en 1999, il est entré à l'université d'Istanbul Çapa, à la faculté de médecine. 

 

En 2005, j'ai obtenu mon master et j'ai commencé à pratiquer à l'hôpital d'État de Yüksekova. Il a obtenu son doctorat à l'hôpital de formation et de recherche Okmeydanı dans le service de chirurgie générale. En tant que spécialiste en chirurgie générale, il a travaillé à l'hôpital d'État Zonguldak Atatürk pendant 5 ans et à l'hôpital de formation et de recherche Sancaktepe Şehit Prof. Dr. İlhan Varank pendant 3 ans. 

 

A travaillé en tant que professeur adjoint à l'université Medipol d'Istanbul, au département de chirurgie générale. Travaille actuellement à l'hôpital Pendik de l'université Medipol.

Lire la suite
Photos Avant et Après
Hilmi Cem Kaya
ENT doctor
3 années d'expérience
Turquie, Istanbul
Medipol University Pendik Hospital

Hilmi Cem Kaya

ENT doctor
3 années d'expérience

Education:

2021 ULUDAĞ ÜNİVERSİTESİ, KULAK BURUN BOĞAZ HASTALIKLARI

2014 EGE ÜNİVERSİTESİ, TIP FAKÜLTESİ

Experience:

2023 - 2023 SAĞLIK BİLİMLERİ ÜNİVERSİTESİ SULTAN ABDÜLHAMİD HAN EĞİTİM VE ARAŞTIRMA HASTANESİ

2021 - 2022 ŞEHİT PROF.DR. İLHAN VARANK SANCAKTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ

Lire la suite

Education:

2021 ULUDAĞ ÜNİVERSİTESİ, KULAK BURUN BOĞAZ HASTALIKLARI

2014 EGE ÜNİVERSİTESİ, TIP FAKÜLTESİ

Experience:

2023 - 2023 SAĞLIK BİLİMLERİ ÜNİVERSİTESİ SULTAN ABDÜLHAMİD HAN EĞİTİM VE ARAŞTIRMA HASTANESİ

2021 - 2022 ŞEHİT PROF.DR. İLHAN VARANK SANCAKTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ

Lire la suite
Photos Avant et Après
Fatma Ela Keskin
Endocrinologist
15 années d'expérience
5.0
28 avis

Fatma Ela Keskin

Endocrinologist
15 années d'expérience
Turquie, Istanbul
Istanbul Florence Nightingale Hospital
Oren-asaf
Endocrinologist
19 années d'expérience
4.4
138 avis
Israël, Tel Aviv
Sourasky Medical Center (Ichilov)

Oren-asaf

Endocrinologist
19 années d'expérience
Le Dr Asaf Oren est médecin-chef à l'unité d'endocrinologie pédiatrique et de diabète de l'hôpital pour enfants Dana-Dwek, spécialisé dans l'endocrinologie pédiatrique et le diabète. Il possède une vaste expérience clinique et universitaire, notamment grâce à des bourses d'études à l'hôpital pour enfants malades de Toronto et à l'hôpital pour enfants "Dana-Dwek" du centre médical de Tel-Aviv, ainsi qu'à des postes d'enseignant à l'école de médecine Sackler et à l'école d'infirmières universitaires Sheinborn de Tel-Aviv.Lire la suite
Le Dr Asaf Oren est médecin-chef à l'unité d'endocrinologie pédiatrique et de diabète de l'hôpital pour enfants Dana-Dwek, spécialisé dans l'endocrinologie pédiatrique et le diabète. Il possède une vaste expérience clinique et universitaire, notamment grâce à des bourses d'études à l'hôpital pour enfants malades de Toronto et à l'hôpital pour enfants "Dana-Dwek" du centre médical de Tel-Aviv, ainsi qu'à des postes d'enseignant à l'école de médecine Sackler et à l'école d'infirmières universitaires Sheinborn de Tel-Aviv.
Lire la suite
Anton Luger
Endocrinologist
44 années d'expérience
4.6
140 avis
L'Autriche, Vienna
Wiener Privatklinik

Anton Luger

Endocrinologist
44 années d'expérience

Professeur de médecine, chef du département d'endocrinologie et de métabolisme, faculté de médecine, université de médecine de Vienne. Membre de plusieurs organisations, telles que la section d'endocrinologie de l'Union européenne des médecins spécialistes et la Société autrichienne d'endocrinologie. Plus de 300 publications dans des revues à comité de lecture couvrant les domaines de la recherche clinique, fondamentale et translationnelle.

Lire la suite

Professeur de médecine, chef du département d'endocrinologie et de métabolisme, faculté de médecine, université de médecine de Vienne. Membre de plusieurs organisations, telles que la section d'endocrinologie de l'Union européenne des médecins spécialistes et la Société autrichienne d'endocrinologie. Plus de 300 publications dans des revues à comité de lecture couvrant les domaines de la recherche clinique, fondamentale et translationnelle.

Lire la suite
Ilana Itzhakov
Endocrinologist
35 années d'expérience
4.4
138 avis
Israël, Tel Aviv
Sourasky Medical Center (Ichilov)

Ilana Itzhakov

Endocrinologist
35 années d'expérience

Le Dr Ilana Itzhakov est endocrinologue au centre médical Ichilov (centre médical Sourasky de Tel-Aviv).

Lire la suite

Le Dr Ilana Itzhakov est endocrinologue au centre médical Ichilov (centre médical Sourasky de Tel-Aviv).

Lire la suite
Uri Eal
Endocrinologist
22 années d'expérience
4.4
138 avis
Israël, Tel Aviv
Sourasky Medical Center (Ichilov)

Uri Eal

Endocrinologist
22 années d'expérience
  • Education
  • Faculté de médecine Sackler, Université de Tel Aviv
  •  
  • Spécialisation
  • Pédiatrie, Endocrinologie pédiatrique
  •  
  • Expérience reconnue
  • Spécialiste en pédiatrie, Spécialiste en pédiatrie, Spécialiste en endocrinologie pédiatrique.
  •  
  • Formation complémentaire
  • 2002-2005. Stage en endocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA
  • 2005-2006 stage en neuroendocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA.
  •  
Expérience clinique1998-2001. Spécialisation en pédiatrie, hôpital pour enfants Dana, centre médical Suraski, Tel Aviv2002 Pédiatre principal, hôpital pour enfants Dana, centre médical Suraski, Tel Aviv2002-2005. - Spécialisation en endocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA2005-2006 Stage en neuroendocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA.2006-2008 Endocrinologue pédiatrique principal, hôpital pour enfants Safra, centre médical Sheba, Tel Hashomer2007 Endocrinologue pédiatrique, services de santé MaccabiDepuis 2008 Endocrinologue pédiatrique principal, hôpital pour enfants Dana-Duak, centre médical Suraski, Tel AvivDepuis 2010. Directeur de la clinique d'endocrinologie et de diabète pédiatrique, hôpital pour enfants Dana-Duak, centre médical Suraski, Tel AvivDepuis 2011. Directeur de la division de neuroendocrinologie pédiatrique, hôpital pour enfants Dana-Duak, centre médical Suraski, Tel Aviv Expérience universitaire2008-2013 Instructeur clinique, département de pédiatrie, faculté de médecine Sackler, université de Tel Aviv. Sackler Tel Aviv University2013-2019 instructeur clinique au département de pédiatrie, faculté de médecine Sackler, université de Tel AvivDepuis 2019 instructeur clinique senior au département de pédiatrie, faculté de médecine Sackler, université de Tel Aviv. Sackler Université de Tel Aviv Participation à des conférencesUne trentaine de présentations à des conférences scientifiques Publications professionnellesUne trentaine de publications professionnelles&nbsp ;Appartenance syndicaleIsraël Medical AssociationIsraël Association for Paediatric EndocrinologyIsraël Association of Endocrinologists Domaines d'intérêt particulier et activitésEndocrinologie pédiatrique et diabète, Neuroendocrinologie
Lire la suite
  • Education
  • Faculté de médecine Sackler, Université de Tel Aviv
  •  
  • Spécialisation
  • Pédiatrie, Endocrinologie pédiatrique
  •  
  • Expérience reconnue
  • Spécialiste en pédiatrie, Spécialiste en pédiatrie, Spécialiste en endocrinologie pédiatrique.
  •  
  • Formation complémentaire
  • 2002-2005. Stage en endocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA
  • 2005-2006 stage en neuroendocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA.
  •  
Expérience clinique1998-2001. Spécialisation en pédiatrie, hôpital pour enfants Dana, centre médical Suraski, Tel Aviv2002 Pédiatre principal, hôpital pour enfants Dana, centre médical Suraski, Tel Aviv2002-2005. - Spécialisation en endocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA2005-2006 Stage en neuroendocrinologie pédiatrique, Cincinnati Children's Hospital, Ohio, USA.2006-2008 Endocrinologue pédiatrique principal, hôpital pour enfants Safra, centre médical Sheba, Tel Hashomer2007 Endocrinologue pédiatrique, services de santé MaccabiDepuis 2008 Endocrinologue pédiatrique principal, hôpital pour enfants Dana-Duak, centre médical Suraski, Tel AvivDepuis 2010. Directeur de la clinique d'endocrinologie et de diabète pédiatrique, hôpital pour enfants Dana-Duak, centre médical Suraski, Tel AvivDepuis 2011. Directeur de la division de neuroendocrinologie pédiatrique, hôpital pour enfants Dana-Duak, centre médical Suraski, Tel Aviv Expérience universitaire2008-2013 Instructeur clinique, département de pédiatrie, faculté de médecine Sackler, université de Tel Aviv. Sackler Tel Aviv University2013-2019 instructeur clinique au département de pédiatrie, faculté de médecine Sackler, université de Tel AvivDepuis 2019 instructeur clinique senior au département de pédiatrie, faculté de médecine Sackler, université de Tel Aviv. Sackler Université de Tel Aviv Participation à des conférencesUne trentaine de présentations à des conférences scientifiques Publications professionnellesUne trentaine de publications professionnelles&nbsp ;Appartenance syndicaleIsraël Medical AssociationIsraël Association for Paediatric EndocrinologyIsraël Association of Endocrinologists Domaines d'intérêt particulier et activitésEndocrinologie pédiatrique et diabète, Neuroendocrinologie
Lire la suite
Naftali Shtern
Endocrinologist
49 années d'expérience
4.4
138 avis
Israël, Tel Aviv
Sourasky Medical Center (Ichilov)

Naftali Shtern

Endocrinologist
49 années d'expérience
Naftali Stern est un médecin très expérimenté en médecine et en endocrinologie, ayant occupé divers postes dans des institutions médicales aux États-Unis et en Israël. Il est actuellement directeur de l'Institut d'endocrinologie du Centre médical de Tel Aviv et professeur de médecine à la Faculté de médecine Sackler de l'Université de Tel Aviv.Lire la suite
Naftali Stern est un médecin très expérimenté en médecine et en endocrinologie, ayant occupé divers postes dans des institutions médicales aux États-Unis et en Israël. Il est actuellement directeur de l'Institut d'endocrinologie du Centre médical de Tel Aviv et professeur de médecine à la Faculté de médecine Sackler de l'Université de Tel Aviv.
Lire la suite
Dr Philipp Riss
Endocrinologist
19 années d'expérience
4.6
140 avis
L'Autriche, Vienna
Wiener Privatklinik

Dr Philipp Riss

Endocrinologist
19 années d'expérience

Le Dr. est chef d'équipe en endocrinologie chirurgicale à l'Université médicale de Vienne. Il est spécialiste en chirurgie générale et viscérale et a obtenu un doctorat en médecine (2005). Il a organisé plusieurs conférences et est membre de plusieurs sociétés médicales. Il dirige actuellement le groupe de travail sur l'endocrinologie chirurgicale à l'université médicale de Vienne. Il a reçu le prix Venia Docendi en 2017 et le prix Sandoz pour la recherche sur la thyroïde en 2010.

Lire la suite

Le Dr. est chef d'équipe en endocrinologie chirurgicale à l'Université médicale de Vienne. Il est spécialiste en chirurgie générale et viscérale et a obtenu un doctorat en médecine (2005). Il a organisé plusieurs conférences et est membre de plusieurs sociétés médicales. Il dirige actuellement le groupe de travail sur l'endocrinologie chirurgicale à l'université médicale de Vienne. Il a reçu le prix Venia Docendi en 2017 et le prix Sandoz pour la recherche sur la thyroïde en 2010.

Lire la suite
Naomi Vayntrub
Endocrinologist
35 années d'expérience
4.4
138 avis
Israël, Tel Aviv
Sourasky Medical Center (Ichilov)

Naomi Vayntrub

Endocrinologist
35 années d'expérience

Professeur, spécialiste en endocrinologie pédiatrique

Consultant en endocrinologie pédiatrique

Lire la suite

Professeur, spécialiste en endocrinologie pédiatrique

Consultant en endocrinologie pédiatrique

Lire la suite
Mehmet Fatih Kilicli
Reproductive endocrinologist
32 années d'expérience
5.0
2 avis
Turquie, Istanbul
Medipol Acibadem District Hospital

Mehmet Fatih Kilicli

Reproductive endocrinologist
32 années d'expérience

Education and Experience

  • 1992 - 1998, Gaziantep University, Faculty of Medicine
  • 2002 – 2015, Cumhuriyet University, Faculty of Medicine, Department of Internal Medicine
  • 2015 – 2024, Bağcılar Medipol Mega University Hospital
  • 2024 – Present, Medipol Acıbadem Hospital
Lire la suite

Education and Experience

  • 1992 - 1998, Gaziantep University, Faculty of Medicine
  • 2002 – 2015, Cumhuriyet University, Faculty of Medicine, Department of Internal Medicine
  • 2015 – 2024, Bağcılar Medipol Mega University Hospital
  • 2024 – Present, Medipol Acıbadem Hospital
Lire la suite
Esra Demir
General practitioner
15 années d'expérience
5.0
2 avis
Turquie, Istanbul
Medipol Acibadem District Hospital

Esra Demir

General practitioner
15 années d'expérience

Education:

  • Degree: Faculty of Medicine, Trakya University, 2009
  • Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
  • Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
  • Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
  • Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
  • Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Lire la suite

Education:

  • Degree: Faculty of Medicine, Trakya University, 2009
  • Medical Specialty: Internal Medicine, Bakırköy Dr. Sadi Konuk Training and Research Hospital, 2010-2014
  • Specialist Doctor: Internal Medicine, Kanuni Sultan Süleyman Training and Research Hospital, 2014-2019
  • Specialist Doctor: Internal Medicine, Turkish Hospital Internal Medicine Clinic, Qatar, 2019-2020
  • Specialist Doctor: Internal Medicine, Istanbul Medipol University Hospital Mega Hospital Internal Medicine Department, 2020-2024
  • Associate Professor Doctor: Internal Medicine, Istanbul Medipol University Medipol Acıbadem Regional Hospital, 2024-Present.

Roles in Projects:

Sub investigator (Assistant Researcher) in the SOUL Study: Cardiovascular Outcome Research of Semaglutide in Type 2 Diabetic Patients, approved by the Turkish Medicines and Medical Devices Agency on May 22, 2019.

Sub investigator (Assistant Researcher) in the international study “SCALE™ Insulin”: Efficacy and Safety of Liraglutide 3.0 mg in Overweight or Obese Patients with Type 2 Diabetes Treated with Basal Insulin (Study Code: NN8022-4272), conducted by Novo Nordisk A.Ş.

Subinvestigator (Assistant Researcher) in the international study NN5401-4266 StepByStep Intensification conducted by Novo Nordisk.

Assistant Researcher in the study "A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes (SUSTAIN 11)" (2019-2020).

Assistant Researcher in the PIONEER 1 study: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.

Lire la suite
Kim Hoon-yub
Endocrinologist
14 années d'expérience
République de Corée, Séoul
Korea University Anam Hospital

Kim Hoon-yub

Endocrinologist
14 années d'expérience

2014 : La première thyroïdectomie orale robotisée au monde développée par Kim Hoon-yub

 

2011 ~ : Fellow de l'International Society of Neuro Monitoring Research

2008 ~ : Membre permanent de la Société coréenne des chirurgiens endoscopiques et laparoscopiques

2008 ~ : Membre permanent de la Société coréenne d'oncologie chirurgicale

2008 ~ : Membre permanent de l'Association Thyroïdienne Asie Océanie

2014 ~ : Professeur chercheur, Société coréenne des chirurgiens endoscopiques et laparoscopiques

2014 ~ : Membre du comité de planification de l'Association coréenne des chirurgiens thyroïdiens et endocriniens, membre du comité consultatif des droits médicaux

2012 ~ : Membre du Forum International de Recherche en Chirurgie

2015 ~ : Membre de l'American Thyroid Association

2015 ~ 2016 : Professeur de recherche, Division de chirurgie de la tête et du cou, Faculté de médecine de l'Université Johns Hopkins, États-Unis

 

 

 

Lire la suite

2014 : La première thyroïdectomie orale robotisée au monde développée par Kim Hoon-yub

 

2011 ~ : Fellow de l'International Society of Neuro Monitoring Research

2008 ~ : Membre permanent de la Société coréenne des chirurgiens endoscopiques et laparoscopiques

2008 ~ : Membre permanent de la Société coréenne d'oncologie chirurgicale

2008 ~ : Membre permanent de l'Association Thyroïdienne Asie Océanie

2014 ~ : Professeur chercheur, Société coréenne des chirurgiens endoscopiques et laparoscopiques

2014 ~ : Membre du comité de planification de l'Association coréenne des chirurgiens thyroïdiens et endocriniens, membre du comité consultatif des droits médicaux

2012 ~ : Membre du Forum International de Recherche en Chirurgie

2015 ~ : Membre de l'American Thyroid Association

2015 ~ 2016 : Professeur de recherche, Division de chirurgie de la tête et du cou, Faculté de médecine de l'Université Johns Hopkins, États-Unis

 

 

 

Lire la suite
Visite du médecin prix sur demande
Thyroïdectomie $7734 - $9139
Plus de traitements
Gonul Catli
Endocrinologist
25 années d'expérience
5.0
4 avis
Turquie, Istanbul
Liv Hospital Vadistanbul

Gonul Catli

Endocrinologist
25 années d'expérience

Medical Interests 

Obesity 

Insulin resistance 

Diabetes 

Hypoglycemia (low sugar) 

Growth retardation and short stature 

Anorexia 

growth hormone deficiency 

Puberty problems (early puberty, delayed puberty, excessive hair growth, menstrual irregularity, polycystic ovary syndrome) 

Turner syndrome 

Thyroid diseases (Goiter, hypothyroidism, hyperthyroidism, Hashimoto’s disease, thyroid nodule) 

Sexual development disorders (small penis, undescended testis, gender ambiguity, hypospadias) 

Adrenal gland diseases (Congenital adrenal hyperplasia, Addison’s disease, Cushing’s syndrome) 

Bone and calcium metabolism diseases (rickets, vitamin D deficiency, osteoporosis) 

Education 

Bachelor’s - Master’s: Ankara University Faculty of Medicine (1998-2004) 

Ph.D. - Specialization in Medicine: Child Health and Diseases, Dr. Sami Ulus Gynecology and Childhood Health and Diseases Training and Research Hospital (2005-2010) 

Ph.D. - Minor specialization: Pediatric Endocrinology, Dokuz Eylul University Faculty of Medicine (2010-2013) 

Experience 

Child Health and Diseases Specialist Diyarbakır Children’s Hospital 2010 

Pediatric Endocrine Minor Assistant Dokuz Eylül University Medical Faculty Hospital 2010-2014 

Pediatric Endocrinology Specialist İzmir Tepecik Training and Research Hospital 2014-2015 

Assistant Professor Izmir Katip Celebi University Faculty of Medicine 2015-2016 

Associate Professor Izmir Katip Celebi University Faculty of Medicine 2016-2021 

Pediatric Endocrinology Associate Professor Ulus Liv Hospital 2021- Present 

Pediatric Endocrinology Associate Professor Vadistanbul Liv Hospital 2021- Present

Memberships 

Aegean Child Endocrine and Diabetes Association, Member, 2010 

Pediatric Endocrinology and Diabetes Association, Member, 2010 

Growing Child Association, Member, 2014 

European Society of Pediatric Endocrinology (ESPE), Member, 2016

Lire la suite

Medical Interests 

Obesity 

Insulin resistance 

Diabetes 

Hypoglycemia (low sugar) 

Growth retardation and short stature 

Anorexia 

growth hormone deficiency 

Puberty problems (early puberty, delayed puberty, excessive hair growth, menstrual irregularity, polycystic ovary syndrome) 

Turner syndrome 

Thyroid diseases (Goiter, hypothyroidism, hyperthyroidism, Hashimoto’s disease, thyroid nodule) 

Sexual development disorders (small penis, undescended testis, gender ambiguity, hypospadias) 

Adrenal gland diseases (Congenital adrenal hyperplasia, Addison’s disease, Cushing’s syndrome) 

Bone and calcium metabolism diseases (rickets, vitamin D deficiency, osteoporosis) 

Education 

Bachelor’s - Master’s: Ankara University Faculty of Medicine (1998-2004) 

Ph.D. - Specialization in Medicine: Child Health and Diseases, Dr. Sami Ulus Gynecology and Childhood Health and Diseases Training and Research Hospital (2005-2010) 

Ph.D. - Minor specialization: Pediatric Endocrinology, Dokuz Eylul University Faculty of Medicine (2010-2013) 

Experience 

Child Health and Diseases Specialist Diyarbakır Children’s Hospital 2010 

Pediatric Endocrine Minor Assistant Dokuz Eylül University Medical Faculty Hospital 2010-2014 

Pediatric Endocrinology Specialist İzmir Tepecik Training and Research Hospital 2014-2015 

Assistant Professor Izmir Katip Celebi University Faculty of Medicine 2015-2016 

Associate Professor Izmir Katip Celebi University Faculty of Medicine 2016-2021 

Pediatric Endocrinology Associate Professor Ulus Liv Hospital 2021- Present 

Pediatric Endocrinology Associate Professor Vadistanbul Liv Hospital 2021- Present

Memberships 

Aegean Child Endocrine and Diabetes Association, Member, 2010 

Pediatric Endocrinology and Diabetes Association, Member, 2010 

Growing Child Association, Member, 2014 

European Society of Pediatric Endocrinology (ESPE), Member, 2016

Lire la suite
Cigdem Arslan
Colorectal surgeon
17 années d'expérience
5.0
2 avis
Turquie, Istanbul
Medipol Bahçelievler Hospital

Cigdem Arslan

Colorectal surgeon
17 années d'expérience

Experience 

  • 2016 - 2017

İSTİNYE UNIVERSITY FACULTY OF MEDICINE

  • 2016 - 2017

Liv Hospital

  • 2016 - 2017

Liv Hospital Ulus

  • 2015 - 2016

Acıbadem Bodrum Hospital

  • 2014 - 2015

Tatvan State Hospital

  • 2013 - 2015

Tatvan State Hospital

  • 2012 - 2013

CLEVELAND CLINIC

  • 2007 - 2014

Dokuz Eylul University Faculty of Medicine

Education 

  • 2013

DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY

  • 2013

Dokuz Eylül University, General Surgery

  • 2007

AKDENİZ UNIVERSITY, FACULTY OF MEDICINE

  • 2007

International Peer-Reviewed Journal Articles:

Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.

  • Authors: AĞALAR CİHAN, SÖKMEN SELMAN, ARSLAN ÖZŞAHİN NACİYE ÇİĞDEM, ALTAY CANAN, BAŞARA AKIN IŞIL, CANDA ARAS EMRE, OBUZ FUNDA
  • Journal: Techniques in Coloproctology
  • Year: 2020
  • Volume: 24(4)
  • Pages: 301-308
  • DOI: 10.1007/s10151-020-02159-z
  • Publication Number: 6776368

Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.

  • Authors: Terzi Cem, Bingül Mustafa, ARSLAN NACİYE ÇİĞDEM, ÖZTÜRK ERSİN, CANDA ARAS EMRE, IŞIK ÖZGEN, YILMAZLAR AHMET TUNCAY, OBUZ FUNDA, Görken Birkay, KURT MERAL, ÜNLÜ ŞADİYE MEHTAT, UĞRAŞ NESRİN, Kanat Özkan, ÖZTOP İLHAN
  • Journal: Colorectal Disease
  • Year: 2020
  • Volume: 22(3)
  • Pages: 279-288
  • DOI: 10.1111/codi.14867
  • Publication Number: 6012919

Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.

  • Authors: ÖZDENKAYA YAŞAR, OLMUŞÇELİK OKTAY, BASIM PELİN, SAKA BURCU, ARSLAN NACİYE ÇİĞDEM
  • Journal: Acta Cirurgica Brasileira
  • Year: 2019
  • Volume: 34(8)
  • Publication Number: 5242669

Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.

  • Authors: CANDA ARAS EMRE, ARSLAN NACİYE ÇİĞDEM, Terzi Cem, Sokmen Selman, YAVUZŞEN TUĞBA, Ozkardesler Sevda, Unlu Mehtat, OBUZ FUNDA, FÜZÜN MEHMET
  • Journal: World Journal of Surgical Oncology
  • Year: 2018
  • Volume: 16(1)
  • Pages: 70-74
  • DOI: 10.1186/s12957-018-1369-7
  • Publication Number: 4863133

Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.

  • Authors: Atasoy Gulsen, ARSLAN NACİYE ÇİĞDEM, Elibol Funda, SAĞOL ÖZGÜL, OBUZ FUNDA, SÖKMEN SELMAN
  • Journal: Surgery Today
  • Year: 2018
  • Volume: 48(12)
  • Pages: 1040-1051
  • DOI: 10.1007/s00595-018-1690-3
  • Publication Number: 4863005

Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?

  • Authors: Terzi Cem, Sokmen Selman, ARSLAN NACİYE ÇİĞDEM, Ozkardesler Sevda, DURAL CEMIL, OBUZ FUNDA, CANDA ARAS EMRE, GÖKTÜRK ÜMIT KELEŞTEN
  • Journal: International Journal of Surgery
  • Year: 2018
  • Volume: 51
  • Pages: 156-160
  • DOI: 10.1016/j.ijsu.2018.01.010
  • Publication Number: 4855751

Contributions to Conferences:

Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.

  • Authors: CANDA ARAS EMRE, Sokmen Selman, Terzi Cem, ARSLAN NACİYE ÇİĞDEM, OBUZ FUNDA
  • Conference: European Society of Surgical Oncology (ESSO) Congress
  • Year: 2018
  • Location: Budapest, Hungary

Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.

  • Authors: ARSLAN NACİYE ÇİĞDEM, Terzi Cem, Sokmen Selman, CANDA ARAS EMRE, OBUZ FUNDA
  • Conference: European Association for Endoscopic Surgery (EAES) Congress
  • Year: 2017
  • Location: Frankfurt, Germany
Lire la suite

Experience 

  • 2016 - 2017

İSTİNYE UNIVERSITY FACULTY OF MEDICINE

  • 2016 - 2017

Liv Hospital

  • 2016 - 2017

Liv Hospital Ulus

  • 2015 - 2016

Acıbadem Bodrum Hospital

  • 2014 - 2015

Tatvan State Hospital

  • 2013 - 2015

Tatvan State Hospital

  • 2012 - 2013

CLEVELAND CLINIC

  • 2007 - 2014

Dokuz Eylul University Faculty of Medicine

Education 

  • 2013

DOKUZ EYLÜL UNIVERSITY FACULTY OF MEDICINE, FACULTY OF MEDICINE/DEPARTMENT OF SURGICAL MEDICAL SCIENCES/DEPARTMENT OF GENERAL SURGERY

  • 2013

Dokuz Eylül University, General Surgery

  • 2007

AKDENİZ UNIVERSITY, FACULTY OF MEDICINE

  • 2007

International Peer-Reviewed Journal Articles:

Title: The impact of sarcopenia on morbidity and long-term survival among patients with peritoneal metastases of colorectal origin treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a 10-year longitudinal analysis of a single-center experience.

  • Authors: AĞALAR CİHAN, SÖKMEN SELMAN, ARSLAN ÖZŞAHİN NACİYE ÇİĞDEM, ALTAY CANAN, BAŞARA AKIN IŞIL, CANDA ARAS EMRE, OBUZ FUNDA
  • Journal: Techniques in Coloproctology
  • Year: 2020
  • Volume: 24(4)
  • Pages: 301-308
  • DOI: 10.1007/s10151-020-02159-z
  • Publication Number: 6776368

Title: Randomized controlled trial of 8 weeks’ vs 12 weeks’ interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.

  • Authors: Terzi Cem, Bingül Mustafa, ARSLAN NACİYE ÇİĞDEM, ÖZTÜRK ERSİN, CANDA ARAS EMRE, IŞIK ÖZGEN, YILMAZLAR AHMET TUNCAY, OBUZ FUNDA, Görken Birkay, KURT MERAL, ÜNLÜ ŞADİYE MEHTAT, UĞRAŞ NESRİN, Kanat Özkan, ÖZTOP İLHAN
  • Journal: Colorectal Disease
  • Year: 2020
  • Volume: 22(3)
  • Pages: 279-288
  • DOI: 10.1111/codi.14867
  • Publication Number: 6012919

Title: The effect of fibrin glue in preventing staple-line leak after sleeve gastrectomy: an experimental study in rats.

  • Authors: ÖZDENKAYA YAŞAR, OLMUŞÇELİK OKTAY, BASIM PELİN, SAKA BURCU, ARSLAN NACİYE ÇİĞDEM
  • Journal: Acta Cirurgica Brasileira
  • Year: 2019
  • Volume: 34(8)
  • Publication Number: 5242669

Title: Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.

  • Authors: CANDA ARAS EMRE, ARSLAN NACİYE ÇİĞDEM, Terzi Cem, Sokmen Selman, YAVUZŞEN TUĞBA, Ozkardesler Sevda, Unlu Mehtat, OBUZ FUNDA, FÜZÜN MEHMET
  • Journal: World Journal of Surgical Oncology
  • Year: 2018
  • Volume: 16(1)
  • Pages: 70-74
  • DOI: 10.1186/s12957-018-1369-7
  • Publication Number: 4863133

Title: Magnetic resonance-based pelvimetry and tumor volumetry can predict surgical difficulty and oncologic outcome in locally advanced mid–low rectal cancer.

  • Authors: Atasoy Gulsen, ARSLAN NACİYE ÇİĞDEM, Elibol Funda, SAĞOL ÖZGÜL, OBUZ FUNDA, SÖKMEN SELMAN
  • Journal: Surgery Today
  • Year: 2018
  • Volume: 48(12)
  • Pages: 1040-1051
  • DOI: 10.1007/s00595-018-1690-3
  • Publication Number: 4863005

Title: Is advanced age a hesitation for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer?

  • Authors: Terzi Cem, Sokmen Selman, ARSLAN NACİYE ÇİĞDEM, Ozkardesler Sevda, DURAL CEMIL, OBUZ FUNDA, CANDA ARAS EMRE, GÖKTÜRK ÜMIT KELEŞTEN
  • Journal: International Journal of Surgery
  • Year: 2018
  • Volume: 51
  • Pages: 156-160
  • DOI: 10.1016/j.ijsu.2018.01.010
  • Publication Number: 4855751

Contributions to Conferences:

Title: Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: A single-center experience.

  • Authors: CANDA ARAS EMRE, Sokmen Selman, Terzi Cem, ARSLAN NACİYE ÇİĞDEM, OBUZ FUNDA
  • Conference: European Society of Surgical Oncology (ESSO) Congress
  • Year: 2018
  • Location: Budapest, Hungary

Title: Predictive factors for conversion to open surgery in laparoscopic colorectal surgery.

  • Authors: ARSLAN NACİYE ÇİĞDEM, Terzi Cem, Sokmen Selman, CANDA ARAS EMRE, OBUZ FUNDA
  • Conference: European Association for Endoscopic Surgery (EAES) Congress
  • Year: 2017
  • Location: Frankfurt, Germany
Lire la suite
5.0
2 avis
Visite du médecin prix sur demande
Thérapie à l'iode radioactif $5000 - $7000
Thyroïdectomie $4000 - $5500
Plus de traitements
Nail Paksoy
Oncologist/mammologist
13 années d'expérience
5.0
2 avis
Turquie, Istanbul
Medipol Bahçelievler Hospital

Nail Paksoy

Oncologist/mammologist
13 années d'expérience


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

Lire la suite


PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

 

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

 

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

  • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
  • Role: Subinvestigator

2. PFİZER

  • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
  • Role: Subinvestigator

3. RECITE - AMGEN

  • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
  • Role: Subinvestigator

4. NAVIGATE - BAYER

  • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
  • Role: Subinvestigator

5. RUBY - Tesaro (PRA)

  • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
  • Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

  • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
  • Role: Subinvestigator

7. ASTRA ZENECA

  • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
  • Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

  • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
  • Role: Subinvestigator
  •  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
  • Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

  • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
  • Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

  • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
  • Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

  • Authors: Paksoy, Nail, et al.
  • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

  • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
  • Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

  • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
  • Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

  • Authors: HAS SIMSEK, Duygu, et al.
  • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

  • Authors: FERHATOGLU, Ferhat, et al.
  • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

  • Authors: TURAL, Deniz, et al.
  • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

  • Authors: GÜRBÜZ, Mustafa, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

  • Authors: AY, Seval, et al.
  • Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

  • Authors: CIL, Ibrahim, et al.
  • Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

  • Authors: HIZAL, Mutlu, et al.
  • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
  • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

  • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
  • Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

  • Authors: DEMIR, Semra, et al.
  • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

  • Authors: ÖZDEMIR, Seçil Kepil, et al.
  • Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

  • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
  • Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

  • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
  • Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
  • Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

  • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
  • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

  • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
  • Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

  • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
  • Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

  • Authors: Dogan, I., Paksoy, N., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

  • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
  • Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

  • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
  • Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

  • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
  • Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

  • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
  • Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

  • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
  • Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

 

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

  • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

  • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

  • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

  • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

  • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

  • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

  • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

  • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

  • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

 

 

Lire la suite
5.0
2 avis
Visite du médecin prix sur demande
Thérapie à l'iode radioactif $5000 - $7000
Thyroïdectomie $4000 - $5500
Plus de traitements